Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Conference Presentation (February 2015)
28 slides from Biorestorative Therapies's conference presentation, Feb 9, 2015
Slide 1: BioRestorative Therapies
BioRestorative Therapies Atom Cell Biotechnology Company Inmosatons Contorence | February 22015
Slide 2: Forward Looking Statements
Forward Looking Statements | incain iateroni concerg i sya eters Tharp, hehe “Company trea ee ting tren tele! stan change faces cheep
Slide 3: BioRestorative Therapies (BRT)
BioRestorative Therapies (BRT) Research and Development focus cell basod therapies bréxDISC™ Mesenchymal stem cells for the treatment of chronic Lumbar Dise Disease (cLDD) Lead therapeutic product — successful pre-IND meeting ThermoSten® Brown adipose tissue preclinical program for the treatment of
Slide 4: Lead Therapeutic Product: brtxDISC
's Lead Therapeutic Product: brixD/ISC™ | Addressing the pathophysiology and symptoms of intervertebral disc diseas: .<
Slide 5: brtxDISC Treatment for Lumbar Disc Disease
brtxDISC™ Treatment for Lumbar Disc Disease | br&xDISC™ is BioRestorative Therapies’ lead product candidate brtxD1SC™ is an autologous hypoxic cultured Mesenchymal Stem Cell (MSC) product derived from adult human bone marrow formulated with a proprietary carrier "13/132.840 Methods and Compositions
Slide 6: The Market Opportunity: Lower Back Pain (LBP)
The Market Opportunity: Lower Back Pain (LBP) | LEP is the most common, disabling and costly musculoskeletal problem ‘Global population prevalence of LBP 184% of populace with an occurrance during lifetime 2396 with pain recurrence within 6 months 119% with chronic LAP (Out of 291 medical conditions
Slide 7: The Problem: No Good Treatments for Lower Back Pain
The Problem: No Good Treatments for Lower Back Pain 2] “Today's treatments do not address the pathophyslology ofthe disease Non-Surgieal treatments Physical therapy and weight toss Nonsteroidal athintammatory drugs Spinal manipulation (chiropractic care) Epidural steroid injections Surgical treatmen
Slide 8: The Solution: brtxDISC to treat Lumbar Disc Disease
The Solution: brixD/SC™ to treat Lumbar Disc Disease | “The clinical benefit of mesenchymal stem cells (MSCs) is due to a number of mechanisms that act upon the site of pathology in the aise Replacement MSCs differentiation into chondrocytes Repair/Regeneration: Activation of certain beneficial sign
Slide 9: brtxDISC Treatment Process
brtxDISC™ Treatment Process | brtxDISC™ production begins with the physician collecting (1) bone "marrow and (2) blood plasma from the patient Bone marrow harvested from the patient's ilac crest under a local anesthesia Peripheral blood collected trom the patient Physician sends patient bone marrow
Slide 10: Clinical Results from a Physician Sponsored Study
Clinical Results from a Physician Sponsored Study Patients recelved injection of autologous Mesenchymal Stem Cells to the intervertebral ci ‘Autologous mesenchymal stems cells are safe [No adverse events observed ‘Maxienum dose of 40 milion stem cells wel tolerated Mesenchymal stems cells are effect
Slide 11: Impact of Stem Cells on Disc Morphology
Impact of Stem Cells on Dise Morphology | i Before stem call ‘After stem call treatment ‘Stem cells may have a significant impact on the morphology of the disc and bring relief of symptoms
Slide 12: Clinical Development Plans
brtxDISC™ is an autologous MSC product injected into the intervertobral Clinical Development Plans | dive: MSCs will Be formulated with a proprietary carrion “Therapeutic appation of bvtxDISC™ in andard 206 35 inch wiroducer need ise ‘Company envisions conducting Phase 1/2a, Phase 20. Phase 3 cnicl
Slide 13: brtxDISC Clinical Trial Principal Investigators
brtxDISC™ Clinical Trial Principal Investigators | Gregory & Lutz, M.D.; BRT Chief Medical Advisor for Spine Medicine Physiatrstin-Chiet Ementus for Hospital fr Special Surgery (HSS) and is a member ofthe Boatd of Trustees Regenerative Medicine clinica tal experience Associate Professor of Clinical
Slide 14: Target Physicians Likely To Treat Discs with Stem Cells
Target Physicians Likely To Treat Discs with Stem Cells, Large poo! of physicians in the United States that will use brtxb/SC™ Physicians currently trained and skiled in performing spinal Injections are the target physicians for injections of briD/SC™ Interventional physiatrists (physical medicine p
Slide 15: brtxDISC Revenue Assumptions
brtxDISC™ Revenue Assumptions brexDISC™ alfective in a wide spectrum of lumbar disc dlsease (ror ID to protrusions (o moderate/sawere disc degeneration) [Non-steep learning curve for physicians Up to 10% market penetration inthe frst year '515,000 price per procedure (acceptable to out-of-pocket ear
Slide 16: Pipeline Overview and Anticipated Progress in 2015
Pipeline Overview and Anticipated Progress in 2015 | i aoe nc Zs = on
Slide 17: Market Adoption Strategy
Phase 3 study showing a cinically meaningful atfect of MSCs treating dise protrusions will help drive market adoptio Market Adoption Strategy | Long term follow-up data confirming the safety and efficacy of the therapy ‘Company plans to conduct other supportive studies Promotional activities at spin
Slide 18: Strategic Partnerships for Distribution
Strategic Partnerships for Distribution 3 partner will be sought forthe ing and distribution of fvexD1Se™ Partner characteristics include ‘Sales force with presence in the ‘spinelorthopedic care setting Expertise and vision forthe ‘row of te regenerative medicine market BloRestorative product pipeli
Slide 19: ThermoStem Program (Brown Fat Stem Cells)
ThermoStem® Program (Brown Fat Stem Cells) Potential Treatments for Metabolic Diseases Magnification of brown adipose derived stem ces cultured and differentiated into brown adipocytes on porous extracellular matrix scaffolds
Slide 20: Metabolic Platform Program
Metabolic Platform Program Obesity Hypertension Myopathies Diabetes Atherosclerosis ysipidaemia
Slide 21: ThermoStem Brown Fat Program
ThermoStem® Brown Fat Program “One of the most powertul organs in the Body... Since it consumes both glucose ‘and fatty acids. it is possible we could uilize brown fat fo treat obesity and ‘metabolic dystunciion seen in dabates and hyperlipidemia. Infants have a larger population of brown fat that i
Slide 22: BRT February 2014 Publication in STEM CELLS Journal
BRT February 2014 Publication in STEM CELLS Journal
Slide 23: BioRestorative Therapies/Pfizer Collaboration
BioRestorative Therapies/Pfizer Collaboration Jointly conducting a study entitled "Development and Validation of a Human Brown Adipose Gall Model” BRT has a collection of human brown adipose tissue samples, pre-adipocyte cell ines and immortalized cell ines (Characterization of identity and metaboli
Slide 24: Preclinical Study Results on Glucose and Body Weight
Preclinical Study Results on Glucose and Body Weight Basal Blood Glucose Levels Body Weight tee A) Glucose eves of mies transplanted wth BADSCiacatede and conve (©) Weights of ‘mize wanaplanted with BADSC/acatfolss. and contol
Slide 25: Preclinical Study Results on Triglyceride and Cholesterol Levels
Preclinical Study Results on Triglyceride and Cholesterol Levels “Trig = tt mova. Tro — vema/at. Chol ~ ett mora. Chol — be malt. we 115816, ra0814 12616, r25e12 aM Mth 1a7a13— 159821 ya2e1s 131410 yeieis 190426 ya0814 136824 ‘ova Sane tese14 188816 ae tant zeaeaa 251322 426819 120818,
Slide 26: BioRestorative Therapies Pipeline Summary
BioRestorative Therapies Pipeline Summary Intervertebral Disc Therapeutic Program ‘brxDIEC™ Allogeneic Brown Fat Therapeutic Program
Slide 27: In Summary
In Summary brxpiso™ ‘Successful pre-IND meeting with FDA Expect to commence clinical tral by year end Thermostem® ‘Maintenance and regulation of metabolism Metabolic Platform (Brown Fat) Program addresses large markets Pfizer collaboration Deep expertise in stem ceil biology and public management —
Slide 28: BioRestorative Therapies
biorestordt\ve therapies OTCBB: BRTX
BioRestorative Therapies — Conference Presentation (February 2015) on 6ix